Pfizer-BioNTech updated COVID shot shows strong immune response in high-risk groups
A total of 100 adults were enrolled in the trial
(Reuters): Pfizer (PFE.N), opens new tab and partner BioNTech (22UAy.DE), opens new tab said on Monday their updated COVID-19 vaccine showed an increased immune response in adults aged 65 and older as well as those aged 18 through 64 with at least one underlying risk condition.
Preliminary data from an ongoing late-stage trial showed at least a four-fold increase in levels of LP.8.1-neutralizing antibody after receiving the updated COVID-19 vaccine, the companies said.
A total of 100 adults were enrolled in the trial.
This study was conducted to provide additional information about immunological effects of the vaccine and is not intended to replace the post-marketing commitments requested by the US health regulator.
Saudi-led coalition orders evacuation of Yemen oil facility in Sanaa ahead of operation
- 18 hours ago
I only bought Pokémon Legends: Z-A during Prime Day, and it’s still on sale
- 10 hours ago
Four killed as Rehman Baba Express train derails near Multan
- a day ago
Funeral prayers of two martyred officers of Mushshak crash offered at Chaklala Garrison
- 20 hours ago
Two US cities could soon ban one of the world’s most controversial foods
- 8 hours ago
The liver transplant system tried to fix its sex bias. Did it work?
- 8 hours ago
Pakistan Army conducts successful test launch of hypersonic Fatah-2 extended range missile: ISPR
- 21 hours ago
Hands-on with Amazon’s Alexa Tablet 12 Pro and its wild new matte display
- 10 hours ago
Apple to unveil new smart home products, showcasing updated Siri AI
- a day ago
Resolution concerning imposition of emergency in KP and Presidential Order presented in NA
- 7 minutes ago
Anthropic launches free AI security scans for open-source projects
- 10 hours ago
Tim Cook says ‘I’m not meddling’ in the new Apple CEO’s business
- 10 hours ago
